Ranolazine Tablet, Extended Release
Product Images NDC 0615-8611

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Ranolazine (NDC 0615-8611). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Ranolazine 8611 1)

Structure (Ranolazine 8611 1)
Chemical structure diagram of ranolazine, depicting its molecular composition and arrangement, corresponding to the active ingredient in the ranolazine extended-release tablet product.*
FDA Label Image

Principal Display Panel (Ranolazine 8611 2)

Principal Display Panel (Ranolazine 8611 2)
Label for Ranolazine Extended-Release Tablets 500 mg by NCS HealthCare of KY, LLC dba Vangard Labs. The label indicates Rx only status, a quantity of 30 tablets, and packaging by Vangard in Glasgow, KY. Storage instructions and usage cautions are included, emphasizing swallowing tablets whole and institutional use only. Multiple barcodes and lot number 8611 are displayed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.